The Government of Chile announced last Friday the free delivery of pre-exposure prophylaxis pills (Prep), Medicamernto that prevents the contagion of HIV; during the first quarter of 2019.
For this, the authorities of Chile, a country that has seen duplicate numbers of people infected with the virus over the past seven years, met with members of the Movement of Integration and Homosexual Liberation (Movilh), in order to define the protocols that regulate its use next year.
"The prep tablets can reduce the chance of getting the virus during sexual practices by more than 90% if taken daily. For this reason, there must be a protocol that guides people about their real effects and encourages them to privilege safe sexual practices, since it is not the idea that the tablet causes relaxation, "he said, in charge of Movilh Health Area, Diego Rius.
As detailed by the Minister of Health, Emilio Santelices, The prep tablet is part of a new plan against AIDS and HIV, and will be applied as a preventative treatment in high risk populations.
How it works?
According to the Centers for Disease Control and Prevention in the United States (CDC), if the prep is taken daily, it is achieved reduce by more than 90% the chances of getting the virus that causes AIDS through sex or by 70% for the use of needles that are not sterilized or used by multiple people.
The Prep contains emtricitabine i tenofovir, Two medications that are also used in antiretrovirals because they can reduce the amount of the virus in the blood and prevent it from multiplying.
Pills do not work as a vaccine since they do not generate antibodies but that they need their daily intake so that emtricitabine and tenofovir are present in the blood at the time of contagion and prevent HIV from being established in # 39 ; organism;
Before swallowing, it is necessary to check the good condition of the kidneys and liver, as the pill may cause disorders in these organs.
It was the American pharmaceutical company Gilead Sciences which started marketing this medication in 2012, under the brand name Truvada. It is estimated that the commercial value of the monthly treatment reaches 600 dollars.
Years later, the Mood Health Organization (WHO) began recommending its use to prevent HIV among high-risk groups, such as sex workers or couples of infected patients.
According to figures from Onusida referring to 2017, there are 67,000 people in Galicia infected with the HIV virus, of which 39,001 are being treated, while projections point to an increase of those affected up to 100,000 for the end of the year. this year.